Stocklytics Platform
Asset logo for symbol NLSP
NLS Pharmaceutics AG
NLSP
43
$0.27arrow_drop_up82.43%$0.12
Penny Stock

Performance History

Chart placeholder
Key Stats
Open$0.37
Prev. Close$0.14
EPS-0.32
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap4941574.00
PE Ratio-
LOWHIGH
Day Range0.23
0.46
52 Week Range0.11
1.53
Ratios
P/B Ratio4.84
Revenue-
Operating M. %0.00%
Earnings$0.00
Earnings Growth %26.21%
EBITDA Margin %-
ROE %-862.92%
EPS-0.32

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

Analyst Ratings

Correlated Companies

Price$891.46
Perf. (24h)
arrow_drop_up0.72%$6.45
Market Cap$834.88B
Price$481.04
Perf. (24h)
0.00%$0.00
Market Cap$451.06B
Price$145.64
Perf. (24h)
arrow_drop_down0.20%-$0.30
Market Cap$350.26B
Price$127.99
Perf. (24h)
arrow_drop_up0.38%$0.49
Market Cap$327.94B

About NLS Pharmaceutics AG (NLSP)

NLS Pharmaceutics AG, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience to treat excessive daytime sleepiness and cataplexy; and Nolazol for the treatment of ADHD. The company also developing NLS-4, a selective dopamine reuptake inhibitor to prevent rare sleep disorders; NLS-3, a repurposed reverse ester of methylphenidate for treatment of ADHD; NLS-8, a melatonin ML1A receptor agonist, improved scopolamine-induced amnesia; NLS-11, a norepinephrine and dopamine reuptake inhibitor and muscarinic M1, M2, M3 receptor antagonist; and NLS-12, a norepinephrine and dopamine reuptake inhibitor and muscarinic M4 receptor antagonist. NLS Pharmaceutics AG was incorporated in 2015 and is based in Zurich, Switzerland.

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Alexander Zwyer M.B.A.
Headquarters
Zurich
Employees
0
Exchange
NASDAQ
add NLS Pharmaceutics AG to watchlist

Keep an eye on NLS Pharmaceutics AG

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help
What is NLS Pharmaceutics AG's (NLSP) price per share?

The current price per share for NLS Pharmaceutics AG (NLSP) is $0.27. The stock has seen a price change of $0.12 recently, indicating a 82.43% change. This reflects the stock's recent market performance and investor sentiment.

help
What is the 52-week high and low for NLS Pharmaceutics AG (NLSP)?

For NLS Pharmaceutics AG (NLSP), the 52-week high is $1.53, which is 466.67% from the current price. The 52-week low is $0.11, the current price is 143.24% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help
Is NLS Pharmaceutics AG (NLSP) a growth stock?

NLS Pharmaceutics AG (NLSP) has shown an average price growth of 0.41% over the past three years. It has received a score of 11 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying NLS Pharmaceutics AG as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help
What is NLS Pharmaceutics AG (NLSP) stock price performance year to date (YTD)?

As of the latest data, NLS Pharmaceutics AG (NLSP) has a year-to-date price change of -54.07%. Over the past month, the stock has experienced a price change of 52.54%. Over the last three months, the change has been 0.07%. Over the past six months, the figure is -41.15%.

help
Is NLS Pharmaceutics AG (NLSP) a profitable company?

NLS Pharmaceutics AG (NLSP) has a net income of -$12.17M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 0% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. Operating income is noted at -$11.81M. Furthermore, the EBITDA is -$11.8M.

help
What is the market capitalization of NLS Pharmaceutics AG (NLSP)?

NLS Pharmaceutics AG (NLSP) has a market capitalization of $4.94M. The average daily trading volume is 36.11M, indicating the stock's liquidity and investor engagement.

News

email

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level